X

Trial Profile

A Randomized Phase 2 Clinical Trial of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cixutumumab (Primary) ; Cetuximab
Indications Colorectal cancer
Focus Pharmacogenomic; Therapeutic Use
Sponsors Eli Lilly and Company; ImClone Systems

Most Recent Events

16 Aug 2010 Results published in the Journal of Clincal Oncology.
16 Aug 2010 Status changed from active, no longer recruiting to completed, based on an article published in the Journal of Clincal Oncology.
16 Aug 2010 Primary endpoint 'Objective clinical response rate' has not been met, according to an article published in the Journal of Clincal Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com